Search | Clinical Trials Finder

Conditions: Osteoarthritis
Interventions: Acupuncture; Procedure
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 40 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Carcinoma, Renal Cell
Interventions: Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more

Conditions: Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
Interventions: Carfilzomib, Irinotecan; Drug
Lead sponsor: Cancer Research and Biostatistics Clinical Trials Consortium; Network
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 8
States / cities: Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more

Conditions: Metastatic, Uveal Melanoma
Interventions: 75mg selumetinib, placebo, Dacarbazine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more

Conditions: Head and Neck Cancer
Interventions: ADP-A2M4 in combination with pembrolizumab.; Genetic
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Phoenix, Arizona • San Diego, California • Kansas City, Kansas + 5 more

Conditions: Chronic Nonmalignant Pain
Interventions: Buprenorphine transdermal patch; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 19
States / cities: Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 16 more

Conditions: Recurrent Cervical Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Stage III Vaginal Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Vulvar Cancer, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer
Interventions: triapine, laboratory biomarker analysis, external beam radiation therapy, brachytherapy, cisplatin, pharmacological study; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: Docetaxel, Degarelix, Bicalutamide, Ferumoxytol-enhanced MRI imaging; Drug · Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Stroke With Hemiparesis
Interventions: Music & Physical Therapy; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Aging, Accidental Falls
Interventions: tES (transcranial electrical stimulation); Other
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 60 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Roslindale, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Combination of pimecrolimus and fluticasone, pimecrolimus; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Denver, Colorado • Chicago, Illinois • Houston, Texas

Conditions: Phenylketonuria
Interventions: GMP Diet/GMP Medical Foods, AA Diet/AA Medical Foods; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 12 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts • Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: toremifene, conventional surgery, neoadjuvant therapy; Drug · Procedure
Lead sponsor: Joel Nelson, MD; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Interventions: AMXT1501, DFMO; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 13 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more

Conditions: Myelodysplastic Syndromes
Interventions: DEC-C, MyeloSeq-HD; Drug · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Tuvusertib, X-Ray Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 14
States / cities: Augusta, Georgia • Chicago, Illinois • Iowa City, Iowa + 8 more

Conditions: Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Toripalimab-tpzi, Cisplatin, Docetaxel; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pancreatic Cancer
Interventions: NP137; Drug
Lead sponsor: Aram Hezel; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions: Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension, Hypertension Complicated
Interventions: RBPM, MII; Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16,895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Boston, Massachusetts • Quincy, Massachusetts • Roslindale, Massachusetts

Conditions: Lung Cancer, Non-Small Cell
Interventions: Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Newark, Delaware • Springfield, Illinois • Rochester, Minnesota + 5 more

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Interventions: Toripalimab, Carboplatin, Cisplatin, Paclitaxel, Radiation Therapy; Drug · Radiation
Lead sponsor: Matthew Spector; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Thrombocytopaenia
Interventions: Eltrombopag, Azacitidine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more

Search by objective public record fields.

Efficacy of Acupuncture With Physical Therapy for Knee Osteo-Arthritis

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

Music Therapy/Physical Therapy Intervention to Enhance Well-being and Functional Recovery Post-stroke

Feasibility of Home-based tES for Older Adults at Risk of Falling

Combination Therapy for Atopic Dermatitis

Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria

Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

PDT For Induction Therapy For Head And Neck Cancer

Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Improving Hypertension Control in Safety-Net Settings: The Boston Hypertension Equity Alliance in Treatment

A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor

Window of Opportunity in Preserving Laryngeal Function Trial

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)